Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

Despite significant improvements in the signs and symptoms of myelofibrosis (MF), and possible prolongation of patients’ survival, some have disease that is refractory to ruxolitinib and many lose their response over time. Furthermore, patients with ≥3 mutations are less likely to respond to ruxolit...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Newberry, Kate J., Patel, Keyur, Masarova, Lucia, Luthra, Rajyalakshmi, Manshouri, Taghi, Jabbour, Elias, Bose, Prithviraj, Daver, Naval, Cortes, Jorge, Kantarjian, Hagop, Verstovsek, Srdan
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2017
Assuntos:
Myeloid Neoplasia
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5580275/
https://ncbi.nlm.nih.gov/pubmed/28674026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-05-783225
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares